Progression-Free Survival (PFS) by Blinded Independent Central Review (BICR) and Updated Overall Survival (OS) of Sunitinib versus Placebo for Patients with Progressive, Unresectable, Well Differentiated Pancreatic Neuroendocrine Tumor (NET)
Meeting Abstract
